Clear Street Group Inc. Takes $9.32 Million Position in Sarepta Therapeutics, Inc. $SRPT

Clear Street Group Inc. purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 432,996 shares of the biotechnology company’s stock, valued at approximately $9,318,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of SRPT. AQR Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 214.2% during the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 3,671 shares during the period. Great Lakes Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at approximately $224,000. Guggenheim Capital LLC raised its position in shares of Sarepta Therapeutics by 33.5% during the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock worth $783,000 after purchasing an additional 11,497 shares during the last quarter. First Trust Advisors LP raised its position in shares of Sarepta Therapeutics by 59.2% during the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock worth $10,731,000 after purchasing an additional 233,391 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Sarepta Therapeutics by 7.1% during the 2nd quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock worth $1,972,000 after purchasing an additional 7,665 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Up 2.1%

Shares of NASDAQ SRPT opened at $15.31 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $38.09. The firm has a fifty day moving average of $19.23 and a 200-day moving average of $19.75. The stock has a market capitalization of $1.62 billion, a PE ratio of -15.95, a P/E/G ratio of 0.16 and a beta of 0.21. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.16 million. During the same period in the previous year, the company earned ($3.42) EPS. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post 3.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SRPT shares. Wedbush lifted their price objective on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 26th. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday. Citigroup lifted their price objective on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Royal Bank Of Canada lifted their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $24.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.